Relevant bibliographies by topics / PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)"

1

Akhtar, Naveed H., Orrin Pail, Ankeeta Saran, Lauren Tyrell, and Scott T. Tagawa. "Prostate-Specific Membrane Antigen-Based Therapeutics." Advances in Urology 2012 (2012): 1–9. http://dx.doi.org/10.1155/2012/973820.

Full text
Abstract:
Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to significant morbidity and mortality. While significant therapeutic advances have been made, available systemic therapeutic options are lacking. Prostate-specific membrane antigen (PSMA) is a highly-restricted prostate cell-surface antigen that may be targeted. While initial anti-PSMA monoclonal antibodies were suboptimal, the development of monoclonal antibodies such as J591 which are highly specific for the external domain of PSMA has allowed targeting of viable, intact prostate cancer cells. Radiolabeled J591 has demonstrated accurate and selective tumor targeting, safety, and efficacy. Ongoing studies using anti-PSMA radioimmunotherapy with177Lu-J591 seek to improve the therapeutic profile, select optimal candidates with biomarkers, combine with chemotherapy, and prevent or delay the onset of metastatic disease for men with biochemical relapse. Anti-PSMA monoclonal antibody-drug conjugates have also been developed with completed and ongoing early-phase clinical trials. As PSMA is a selective antigen that is highly overexpressed in prostate cancer, anti-PSMA-based immunotherapy has also been studied and utilized in clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
2

Rajasekaran, Ayyappan K., Gopalakrishnapillai Anilkumar, and Jason J. Christiansen. "Is prostate-specific membrane antigen a multifunctional protein?" American Journal of Physiology-Cell Physiology 288, no. 5 (May 2005): C975—C981. http://dx.doi.org/10.1152/ajpcell.00506.2004.

Full text
Abstract:
Prostate-specific membrane antigen (PSMA) is a metallopeptidase expressed predominantly in prostate cancer (PCa) cells. PSMA is considered a biomarker for PCa and is under intense investigation for use as an imaging and therapeutic target. Although the clinical utility of PSMA in the detection and treatment of PCa is evident and is being pursued, very little is known about its basic biological function in PCa cells. The purpose of this review is to highlight the possibility that PSMA might be a multifunctional protein. We suggest that PSMA may function as a receptor internalizing a putative ligand, an enzyme playing a role in nutrient uptake, and a peptidase involved in signal transduction in prostate epithelial cells. Insights into the possible functions of PSMA should improve the diagnostic and therapeutic values of this clinically important molecule.
APA, Harvard, Vancouver, ISO, and other styles
3

Diao, Wei, Huawei Cai, Lihong Chen, Xi Jin, Xinyang Liao, and Zhiyun Jia. "Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals." Current Topics in Medicinal Chemistry 19, no. 1 (March 26, 2019): 33–56. http://dx.doi.org/10.2174/1568026619666190201100739.

Full text
Abstract:
Background: Prostate cancer (PCa) is the most common sex-related malignancy with high mortality in men worldwide. Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of most prostate tumor cells and considered a valuable target for both diagnosis and therapy of prostate cancer. A series of radiolabeled agents have been developed based on the featured PSMA ligands in the previous decade and have demonstrated promising outcomes in clinical research of primary and recurrent PCa. Furthermore, the inspiring response and safety of lutetium-177-PSMA-617 (177Lu-PSMA-617) radiotherapy represent the potential for expanded therapeutic options for metastatic castration-resistant PCa. Retrospective cohort studies have revealed that radiolabeled PSMA agents are the mainstays of the current success, especially in detecting prostate cancer with metastasis and biochemical recurrence. </P><P> Objective: This review is intended to present a comprehensive overview of the current literature on PSMA ligand-based agents for both radionuclide imaging and therapeutic approaches, with a focus on those that have been clinically adopted. </P><P> Conclusion: PSMA-based diagnosis and therapy hold great promise for improving the clinical management of prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
4

Hong, Jeong Hee. "An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer." Korean Journal of Urological Oncology 20, no. 4 (November 30, 2022): 207–22. http://dx.doi.org/10.22465/kjuo.2022.20.4.207.

Full text
Abstract:
Theranostics is a new term which involves the integration of therapy and diagnosis in a single platform. Prostate-specific membrane antigen (PSMA) has emerged to be a novel promising target for both diagnostic imaging and therapeutics of prostate cancer. During the past decade, radiotracers targeting the PSMA for positron emission tomography (PET) have been developed. These PET tracers are small molecular inhibitors that bind the extracellular domain of PSMA. With the recent approval of radioisotope labeled PSMA PET for clinical use, the field of PSMA theranostics has come under the spotlight. Can the preliminary efficacy and safety data on PSMA theranostics may change the prostate cancer landscape? In this review, we will focus on the history of development, approval of drug, and diagnostic and therapeutic performance of PSMA PET in patients with prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
5

Ghosh, Arundhati, Xinning Wang, Eric Klein, and Warren D. W. Heston. "Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness." Cancer Research 65, no. 3 (February 1, 2005): 727–31. http://dx.doi.org/10.1158/0008-5472.727.65.3.

Full text
Abstract:
Abstract Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer. PSMA is a unique cell surface marker, negatively regulated by androgen and extensively used for imaging of hormone refractory carcinomas and metastatic foci. PSMA is a carboxypeptidase with two important enzymatic functions, namely, folate hydrolase and NAALADase. PSMA also exhibits an endocytic function, in which it spontaneously recycles through endocytic vesicles. PSMA is overexpressed at various stages of prostate cancer, including androgen-sensitive and -independent disease, increased in expression with early relapse after therapy. We have used in vitro invasion assays to explore the possible role of PSMA in the metastasis of prostate cancer cells. Androgen-dependent prostate cancer lines, which express PSMA endogenously (e.g., LNCaP, MDA PCa2b, and CWR22Rv1) are less invasive compared with androgen-independent PC3 or DU145 cells, neither of which expresses PSMA. Ectopic expression of PSMA in PC3 cells reduced the invasiveness of these cells, suggesting that this reduction in the invasion capability of PSMA-expressing cells is due to PSMA expression and not to intrinsic properties of different prostate cancer cell lines. Furthermore, knockdown of PSMA expression increased invasiveness of LNCaP cells by 5-fold. Finally, expression of PSMA mutants lacking carboxypeptidase activity reduced the impact of PSMA expression on invasiveness. Thus, it seems that the enzymatic activity is associated with the effect of PSMA on invasiveness.
APA, Harvard, Vancouver, ISO, and other styles
6

Vlachostergios, Panagiotis J., Ioannis Zachos, and Vassilios Tzortzis. "Biomarkers in Prostate-Specific Membrane Antigen Theranostics." Diagnostics 11, no. 6 (June 18, 2021): 1108. http://dx.doi.org/10.3390/diagnostics11061108.

Full text
Abstract:
Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of 177Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.
APA, Harvard, Vancouver, ISO, and other styles
7

Plichta, Kristin A., Stephen A. Graves, and John M. Buatti. "Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer." International Journal of Molecular Sciences 22, no. 22 (November 9, 2021): 12095. http://dx.doi.org/10.3390/ijms222212095.

Full text
Abstract:
Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers. Diagnostic PSMA radiopharmaceuticals are currently used for staging and diagnosis of prostate cancers, and imaging can predict response to therapeutic PSMA radiopharmaceuticals. While mainly used in the setting of metastatic, castrate-resistant disease, clinical trials are investigating the use of PSMA-based therapy at earlier stages, including in hormone-sensitive or hormone-naïve prostate cancers, and in oligometastatic prostate cancers. This review explores the use of PSMA as a theranostic target and investigates the potential use of PSMA in earlier stage disease, including hormone-sensitive metastatic prostate cancer, and oligometastatic prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
8

Dolgushin, M. B., N. A. Meshcheryakova, A. A. Odzharova, V. B. Matveev, D. I. Nevzorov, O. E. Platonova, and P. V. Kochergin. "18F-PSMA-1007 POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF RECURRENT PROSTATE CANCER: CLINICAL OBSERVATION." Cancer Urology 14, no. 3 (October 2, 2018): 134–38. http://dx.doi.org/10.17650/1726-9776-2018-14-3-134-138.

Full text
Abstract:
Objective: demonstration of possibilities of18F-prostate specific membrane antigen-1007 (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) for diagnostic prostate cancer recurrence.The article presents clinical observation of the patient with prostate cancer biochemical recurrence after the multiple treatment.18F-PSMA-1007 PET/CT demonstrates high sensitivity in prostate cancer recurrence diagnostic, in particular with low prostatic specific antigen level.
APA, Harvard, Vancouver, ISO, and other styles
9

Yari, Hooman, Gregory Nkepang, and Vibhudutta Awasthi. "Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer." Materials 12, no. 5 (March 5, 2019): 756. http://dx.doi.org/10.3390/ma12050756.

Full text
Abstract:
Prostate specific membrane antigen (PSMA) is a marker for diagnosis and targeted delivery of therapeutics to advanced/metastasized prostate cancer. We report a liposome-based system for theranostic delivery to PSMA-expressing (PSMA+) LNCaP cells. A lipopolymer (P3) comprising of PSMA ligand (PSMAL), polyethylene glycol (PEG2000), and palmitate was synthesized and post-inserted into the surface of preformed liposomes. These P3-liposomes were loaded with doxorubicin and radiolabeled with 99mTc radionuclide to study their theranostic characteristics. Differential expression of PSMA on LNCaP and PC3 cells was confirmed by immunoblotting as well as by uptake of PSMAL labeled with 18F radionuclide. We found that the uptake of 99mTc-labeled P3-liposomes by LNCaP cells was >3-fold higher than 99mTc-labeled Plain-liposomes; the amount of doxorubicin delivered to LNCaP cells was also found to be >3-fold higher by P3-liposomes. Cell-based cytotoxicity assay results showed that doxorubicin-loaded P3-liposomes were significantly more toxic to LNCaP cells (p < 0.05), but not to PSMA-negative PC3 cells. Compared to doxorubicin-loaded Plain-liposomes, the IC50 value of doxorubicin-loaded P3-liposomes was reduced by ~5-fold in LNCaP cells. Together, these results suggest that surface functionalization of liposomes with small PSMA-binding motifs, such as PSMAL, can provide a viable platform for specific delivery of theranostics to PSMA+ prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
10

Giraudet, Anne-Laure, David Kryza, Michael Hofman, Aurélie Moreau, Karim Fizazi, Aude Flechon, Rodney J. Hicks, and Ben Tran. "PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?" Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110538. http://dx.doi.org/10.1177/17588359211053898.

Full text
Abstract:
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this protein have been created over the past decade and numerous clinical studies have positively demonstrated the tolerance and efficacy of radiolabeled prostate-specific membrane antigen ligands for PSMA radioligand therapy (PRLT). Preliminary results are encouraging that PRLT will become an important addition to the current therapeutic options in a number of settings. Improvement in radiopharmaceutical targeting and combination with other oncological agents are under investigation to further improve its therapeutic efficacy. These encouraging results have led to the development of other therapies using PSMA as a target, such as PSMA–targeted chimeric antigen receptor T-cells, PSMA–targeted antibody drug conjugates, and PSMA–targeted bi-specific T-cell-directed therapy. This narrative review details the current state and advancements in prostate-specific membrane antigen targeting in prostate cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)"

1

Ehrenborg, Linda. "Generation and characterization of a prostate-specific membrane antigen positive eukaryotic cell system for phage selection." Thesis, KTH, Proteinvetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-302128.

Full text
Abstract:
Prostate cancer is one of the most common cancer types worldwide. However, current diagnostic approaches and treatments are invasive and unspecific. Prostate-specific membrane antigen (PSMA) is an ideal biomarker for prostate cancer and can act as a target for therapeutic or diagnostic agents. Previous attempts to develop an affibody with affinity towards PSMA have been unsuccessful, therefore this thesis aimed at making the affibody selections against PSMA more efficient. In this thesis HEK293 cells expressing a modified version of PSMA containing a 3C protease cleavage site were generated, to enable extraction of the extracellular domain of PSMA during the selections. However, further analyses must be performed to determine if the extracellular domain can be successfully cleaved off. To develop an affibody that can be used both in vitro and in vivo, selections will be carried out against recombinant PSMA as well. The recombinant PSMA was previously produced incorporating an Avi tag for site-specific biotinylation and immobilization for the selections. To biotinylate the recombinant PSMA, the enzyme BirA that catalyzes the biotinylation of the Avi tag, was produced. A protein yield of 8.95 mg/liter culture was obtained and the site-specific biotinylation was highly efficient. To evaluate the proposed affibody selection strategy the next step is to determine if cleavage of the PSMA expressed on the HEK293 cells is possible, optimize the cleavage conditions and to start initial selections using the generated HEK293 cells and the produced BirA enzyme.
Prostatacancer är en av de mest förekommande cancertyperna över hela världen. Nuvarande diagnostiska metoder och terapeutiska behandlingar är dock invasiva och ospecifika. Prostataspecifikt membranantigen (PSMA) är en idealisk biomarkör för prostatacancer och kan agera som en målmolekyl för terapeutiska eller diagnostiska ändamål. Tidigare försök att utveckla en affibody med affinitet mot PSMA har inte lyckats, därför var målet med detta examensarbete att effektivisera selekteringen av affibodies mot PSMA. I detta projekt har HEK293 celler som uttrycker en modifierad version av PSMA, innehållande ett 3C-proteas- klyvningsställe, genererats för att möjliggöra extraktion av den extracellulära domänen av PSMA under selekteringen. Ytterligare analyser måste dock utföras för att avgöra om den extracellulära domänen kan klyvas av. För att utveckla en affibody som kan användas både in vitro och in vivo kommer selekteringen att utföras även mot rekombinant PSMA. Rekombinant PSMA har producerats tidigare med en Avi tag för specifik biotinylering och immobilisering under selekteringen. För att biotinylera det rekombinanta PSMA producerades enzymet BirA, som katalyserar biotinyleringen av en Avi tag. Ett proteinutbyte av 8,95 mg/liter kultur erhölls och den specifika biotinyleringen var effektiv. För att utvärdera den föreslagna strategin för selektering av affibodies är nästa steg att avgöra om klyvning av PSMA uttryckt av HEK293 cellerna är möjlig, optimera klyvningsförhållandena och starta initiala selektioner med de genererade HEK293-cellerna och det producerade BirA-enzymet.
APA, Harvard, Vancouver, ISO, and other styles
2

Lynn, Madeleine E. "Synthesis of silica and gold coated gadolinium oxide nanoparticles for magnetic resonance imaging." Thesis, Queensland University of Technology, 2018. https://eprints.qut.edu.au/116750/1/Madeleine_Lynn_Thesis.pdf.

Full text
Abstract:
Gadolinium oxide nanoparticles were coated with silica and functionalised with gold and anti-PSMA antibodies, to create an MRI contrast agent for potential use in the detection of prostate cancer. This work is presented as an alternative to toxic gadolinium based contrast agents, while maintaining high contrast abilities and the potential for selective cell targeting.
APA, Harvard, Vancouver, ISO, and other styles
3

McDonald, Bernadette Catherine. "Characterisation and analysis of the prostate-specific membrane antigen promoter." Thesis, University of York, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.369325.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Vittes, Gisella E. "Developing DNA Vaccines against the Cancer-Related Prostate-Specific Membrane Antigen." Thesis, University of Southampton, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.509466.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Quinn, Gary. "Cloning and characterisation of the promoter for the prostate specific membrane antigen gene : a candidate for targeted gene therapy for prostate cancer." Thesis, University of York, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.288044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tshabalala, Malvin Thabani. "Investigation of non-prostatic in vitro prostate-specific membrane antigen expression in MCF-7 and MDA-MB-231 breast tumour cells." Diss., University of Pretoria, 2020. http://hdl.handle.net/2263/79132.

Full text
Abstract:
Introduction Breast and prostate cancer mutually represent the most commonly occurring malignancies worldwide in women and men, respectively. The mutative state, recurrence capacity, resistance to conventional chemotherapy, low success rate of surgery and risks associated with radiotherapy confound the management of both these malignancies. There are several similarities between breast and prostate cancer, like growth hormone dependence and similar chemotherapeutic interventions. Therapy based on radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) is proving to be a cutting-edge theranostics intervention for prostate cancer. Clinical positron emission tomography (PET) scans have located anti-PMSA binding sites in breast cancer in vivo. This indicates possible non-prostatic expression of PSMA, therefore research focused on understanding the cellular kinetics, PSMA expression profiles using two breast cancer adenocarcinoma cell lines as breast cancer models. This approach was to assess PSMA as a biomarker molecule that can aid in development of more selective, effective and safe diagnostic and therapeutic alternatives for breast cancer. This study was aimed at evaluating PSMA expression of MCF-7 or MDA-MB-231 mammary adenocarcinoma cell lines in comparison to a known high PSMA expressing LNCaP prostate carcinoma and EA.hy926 hybrid vascular endothelial cell line. Methods In vitro cultures of LNCaP’s , a prostatic adenocarcinoma cell line, MCF-7 and MDA-MB-231 breast adenocarcinoma cell lines and endothelial EA.hy926 cells were tested for expression of PSMA by flow cytometry. The LNCaP cells were used a positive control. Cellular localisation of PSMA was achieved utilising confocal microscopy and fluorescently-tagged antibodies in all the cell lines tested. PSMA was quantified in all the cell lines utilising ELISA. Prior to experimentation, a pilot study was undertaken to optimise cell detachment methods. Trypsinisation was compared to mechanical scraping to evaluate a cell detachment method that allowed optimal downline experimentation. Results Findings from three supporting and complementary techniques demonstrate positive PSMA identification, localisation and quantification in all the probed cell lines despite three cell types not having a prostrate origin. Quantitatively, LNCaP cells reported the highest concentration of PSMA followed by the malignant MDA-MB-231 cells, then the MCF-7 cell line and least in EA.hy926 cells. The difference in fluorescence between LNCaP cells and all three investigational cell lines was statistically significant however the difference in fluorescence between the three investigational cell lines was not statistically significant. The PSMA antigen was localised on the cell membrane and diffused within the cytosol in LNCaP cells. The MDA-MB-231, MCF-7 and EA.hy926 cells all exhibited a differential expression pattern of PSMA. These cells showed diffuse cytosolic accumulation and intense circular region accumulation apparently bordering the cell membrane and the cell nucleus. The quantification of PSMA reported the highest concentration as being in LNCaP cells. The MDA-MB-231 cells were second, then the MCF-7 cells and the lowest concentration. Significant differences were seen between the positive control and the investigation cell lines. The difference in concentration between the investigational cell lines was not significant. Finally, cryotome sections of biopsies of tumours from two breast cancer patients were found to show detectable PSMA presence. Discussion Fluorescence is directly proportional to concentration. The high fluorescence of PSMA exhibited by LNCaP cells in the flow cytometry results can be equated to concentration. A fundamental point of departure from which PSMA expression in the breast carcinoma cell lines could be investigated was established. Expression of PSMA is associated with cancer aggression, metastatic progression and increased malignancy. These clinicopathological characteristics support the expression of PSMA seen in MDA-MB-231. Contrastingly, the same characteristics aren’t seen in MCF-7 cells but expression of PSMA was observed. The expression is not entirely dismissible as other luminal A cell lines have also been shown to express PSMA. The EA.hy926 cells are somatic hybrids that are made up of lung A549 cells and HUVEC’s. Lung cancer has been shown to also express PSMA when probed utilising histology. The expression of PSMA in EA.hy926 is the first of its kind but may be attributable to its lung carcinoma makeup. The pattern of expression in the LNCaP confocal microscopy images can be expected. The PSMA antigen is a transmembrane receptor and as such intense fluorescence was seen on the membrane. Expression of PSMA in the cytoplasm has been reported and was equally observed in the LNCaP cells. The investigation cell line showed accumulation of green fluorescence in vesicular bodies bordering the cell membrane and in juxtanuclear positions. The expression of PSMA has been reported in the mitochondria and the green fluorescence at the nucleus could be mitochondrial. The Golgi apparatus and endoplasmic reticulum have also been recognised as potential location of PSMA expression. The localisation of both these organelles at the nucleus along with the expression of PSMA seen close to the nucleus could be associated. Worth noting is the internalisation properties of PSMA. The antigen has an internalisation signal that can be induced by ligand binding or in the absence of a ligand. Upon internalisation the receptors are vesicled and transported either for degradation of for recycling. The vesicular expression seen close to the membrane in the investigational cell lines could be PSMA that is being trafficked for recycling or degradation upon internalisation. The ELISA quantification revealed the levels of PSMA in the positive control are 100-fold greater than those in the investigation cell lines. The ability to translate PSMA targeting in clinical settings is questionable when considering the difference in concentration values. The probing of PSMA in histological slices was positive and showed patterns that are similar to those seen in the monolayer cultures. This shows continuity between two-dimensional cultures and heterogeneous tissue samples. The premise for investigation of PSMA as a potential theranostic target was established through positive identification, localisation and quantification across three independents methods. Conclusion This study is the first of its kind to report reproducible expression of PSMA in the two-dimensional cultures of breast adenocarcinoma MDA-MB-231 and MCF-7 cell lines as well as in the hybrid endothelial EA.hy926 cell line. The results were confirmed by three different techniques where different antibodies were used for the ELISA showing reproducibility in the findings. Moreover, the generated results support the apparent localisation of PSMA in breast cancer patients utilising PSMA targeting radionuclides in PET imaging in a clinical setting. The potential application of this study’s result is stimulating. The success being realised in prostate cancer theranostics through PSMA targeting, may conceivably be realised in other carcinomas, particularly breast carcinoma theranostics.
Dissertation (MSc)--University of Pretoria, 2020.
https://doi.org/10.25403/UPresearchdata.14885454
Pharmacology
MSc
Unrestricted
APA, Harvard, Vancouver, ISO, and other styles
7

Rhee, Handoo V. "Androgen deprivation therapy (ADT), metabolic syndrome and metastatic prostate cancer: In vivo and in vitro assessments of effects of metformin." Thesis, Queensland University of Technology, 2018. https://eprints.qut.edu.au/118290/2/Handoo%20Rhee%20Thesis.pdf.

Full text
Abstract:
This thesis describes a translational research approach to identifying a cancer mechanism driven by metabolic syndrome. It examines the impact of androgen deprivation therapy, its association with metabolic syndrome and prostate cancer progression, and the therapeutic and metabolic benefits of adjuvant metformin. The study investigates with a randomized placebo controlled clinical trial, with characterization of the molecular mechanism of metformin in vitro using conditions to mimic physiological hormonal milieu.
APA, Harvard, Vancouver, ISO, and other styles
8

原田, 直弥. "前立腺がんの核医学画像診断を目的とした放射性分子イメージングプローブの開発に関する研究." 京都大学 (Kyoto University), 2014. http://hdl.handle.net/2433/188733.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Knedlík, Tomáš. "Glutamátkarboxypeptidasa II jako cíl farmaceutického zásahu a molekulární adresa pro léčbu nádorových onemocnění." Doctoral thesis, 2018. http://www.nusl.cz/ntk/nusl-372828.

Full text
Abstract:
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is a membrane metallopeptidase overexpressed on most prostate cancer cells. Additionally, GCPII also attracted neurologists' attention because it cleaves neurotransmitter N-acetyl-L-aspartyl-L-glutamate (NAAG). Since NAAG exhibits neuroprotective effects, GCPII may participate in a number of brain disorders, which were shown to be ameliorated by GCPII selective inhibitors. Therefore, GCPII has become a promising target for imaging and prostate cancer targeted therapy as well as therapy of neuronal disorders. Globally, prostate cancer represents the second most prevalent cancer in men. With the age, most men will develop prostate cancer. However, prostate tumors are life threatening only if they escape from the prostate itself and start to spread to other tissues. Therefore, considerable efforts have been made to discover tumors earlier at more curable stages as well as to target aggressive metastatic cancers that have already invaded other tissues and become resistant to the standard treatment. Since patients undergoing a conventional therapy (a combination of chemotherapy and surgery) suffer from severe side effects, more effective ways of treatment are being searched for. Novel approaches include selective...
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)"

1

Shubham, Shambhavi, Li-Hsien Lin, Ofonime Udofot, Sven Krupse, and Paloma H. Giangrande. "CHAPTER 15. Prostate-specific Membrane Antigen (PSMA) Aptamers for Prostate Cancer Imaging and Therapy." In Drug Discovery, 339–66. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788015714-00339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Denmeade, Samuel. "Prostate-Specific Membrane Antigen." In Encyclopedia of Cancer, 1–5. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_4782-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Denmeade, Samuel. "Prostate-Specific Membrane Antigen." In Encyclopedia of Cancer, 3795–800. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-46875-3_4782.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Denmeade, Samuel. "Prostate-Specific Membrane Antigen." In Encyclopedia of Cancer, 3068–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4782.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Osborne, Joseph R., Kofi Deh, Alok Azad Anand, Neil H. Bander, and Scott T. Tagawa. "Prostate Specific Membrane Antigen-Based Diagnostics." In Prostate Cancer: A Comprehensive Perspective, 445–57. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2864-9_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tagawa, Scott T., Joseph R. Osborne, Shankar Vallabhajosula, Stanley J. Goldsmith, and Neil H. Bander. "Prostate Specific Membrane Antigen-Based Therapeutics." In Prostate Cancer: A Comprehensive Perspective, 459–66. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2864-9_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tuncel, Murat. "Prostate Specific Membrane Antigen Based Imaging." In Anatomy for Urologic Surgeons in the Digital Era, 109–29. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-59479-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Diaz, Juan E., Li-Mei C. Yang, Jorge A. Lamboy, Reginald M. Penner, and Gregory A. Weiss. "Synthesis of a Virus Electrode for Measurement of Prostate Specific Membrane Antigen." In Biosensors and Biodetection, 255–74. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-569-9_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chubinidze, K., B. Partsvania, A. Khuskivadze, G. Petriashvili, and M. Chubinidze. "Development of In Vitro Prostate Cancer Biomarkers on the Basis of Gelatin Matrix Incorporated Gold Nanoparticles Functionalized with Fluorescence Dye and Prostate Specific Membrane Antigen." In Science and Technology of Polymers and Advanced Materials, 381–93. Includes bibliographical references and index.: Apple Academic Press, 2019. http://dx.doi.org/10.1201/9780429425301-27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Emmett, Louise. "Side effects of therapy with radiolabelled prostate specific membrane antigen (PSMA)." In Reference Module in Biomedical Sciences. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-12-822960-6.00150-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)"

1

Murga, Jose D., Wells W. Magargal, Sameer M. Moorji, Vincent A. DiPippo, and William C. Olson. "Abstract A262: Antiandrogen modulation of prostate-specific membrane antigen (PSMA): Dynamics and synergy with PSMA-targeted therapy." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a262.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Siddiqui, Imtiaz A., Vanna Sanna, Vaqar M. Adhami, Sameh M. Shabana, Mario Sechi, and Hasan Mukhtar. "Abstract 3663: Prostate specific membrane antigen (PSMA) targeting nano-EGCG for prostate cancer prevention and treatment." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3663.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Xinning, Warren Heston, Haibin Tian, and Zhenghong Lee. "Abstract 4554: Synthesis and Biological Evaluation of New Ligands Targeting Prostate Specific Membrane Antigen (PSMA)." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4554.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Siddiqui, Imtiaz A., Dhruba J. Bharali, Minakshi Nihal, Vaqar M. Adhami, Rahime Jashari, Shaker A. Mousa, and Hasan Mukhtar. "Abstract 251: Aptamer conjugated prostate specific membrane antigen (PSMA) targeting EGCG nanobioconjugate for prostate cancer prevention and treatment." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-251.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

von Heesen, A., M. Kasoha, E.-F. Solomayer, C. Unger, R. Bohle, C. Zaharia, S. Ezziddin, and I. Juhasz. "Abstract P6-07-25: Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p6-07-25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Siddiqui, Imtiaz A., Dhruba J. Bharali, Rahime Jashari, Vaqar M. Adhami, Shaker A. Mousa, and Hasan Mukhtar. "Abstract 5263: Prostate-specific membrane antigen (PSMA)-targeting nanobioconjugate-encapsulated green tea polyphenol EGCG for prostate cancer prevention and therapy." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-5263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Siddiqui, Imtiaz A., Vaqar M. Adhami, Islam Rady, and Hasan Mukhtar. "Abstract 3725: Pre-clinical evaluation of prostate specific membrane antigen (PSMA) nanobioconjugate encapsulating green tea polyphenol EGCG for prostate cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Akhtar, Naveed H., Joseph Osborne, David M. Nanus, Shankar Vallabhajosula, Stanley J. Goldsmith, Neil H. Bander, and Scott T. Tagawa. "Abstract 4696: Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4696.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pail, Orrin, Gurveen Kaur, Jonathan Dyke, Yuliya Jhanwar, Paul Christos, Allyson Ocean, Manish Shah, et al. "Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-ct413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sun, Michael, Muhammad Niaz, Charlene Thomas, Ariel Schaap, Kristine Lacuna, Panagiotis Vlachostergios, Paul Christos, et al. "Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6511.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)"

1

Byun, Youngjoo. Heterobivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin. Fort Belvoir, VA: Defense Technical Information Center, November 2014. http://dx.doi.org/10.21236/ada613790.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Byun, Youngjoo. Heterobivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin. Fort Belvoir, VA: Defense Technical Information Center, April 2011. http://dx.doi.org/10.21236/ada549277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Byun, Youngjoo. Hetero-bivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada568064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Byun, Youngjoo. Hetero-bivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada592601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

O'Keefe, Denise S., and Warren D. Heston. Characterization of Prostate-Specific Membrane Antigen (PSMA) for Use in Therapeutic and Diagnostic Strategies Against Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada407353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Denmeade, Samuel R. Enzymatic Activation of Peptide Prodrugs by Prostate-Specific Membrane Antigen (PSMA) as Targeted Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2003. http://dx.doi.org/10.21236/ada414810.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Denmeade, Samuel R. Enzymatic Activation of Peptide Prodrugs by Prostate-Specific Membrane Antigen (PSMA) as Targeted Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2005. http://dx.doi.org/10.21236/ada460938.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ghosh, Arundhati. Novel Role of Prostate-Specific Membrane Antigen in Prostate Cancer Invasion and Metastasis. Fort Belvoir, VA: Defense Technical Information Center, April 2007. http://dx.doi.org/10.21236/ada474688.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Anilkumar, Gopalakrishnapillai. Identification and Characterization of the Ligand of Prostate Specific Membrane Antigen. Fort Belvoir, VA: Defense Technical Information Center, January 2005. http://dx.doi.org/10.21236/ada435023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shapiro, Linda. Prostate-Specific Membrane Antigen Regulation of Prostate Tumor Growth, Angiogenesis,and Integrin Signal Transduction. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada580566.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography